



INTRINSIC BIOPROBES, INC.

Contact: Monte L. Cain

Location: Tempe, AZ

Email: monte@intrinsicbio.com

Tel: 425-337-2580

Website: <http://www.intrinsicbio.com>



U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Biotechnology

Company Overview: IBI has created patented tools and techniques that enable high-throughput protein screening and characterization. These innovations represent decades of research and development, are scientifically validated, and provide immediate performance gains to drug development and research organizations. IBI's technologies offer a unique way to screen and characterize proteins with a high-throughput, industrial approach. Our platform can either be incorporated directly into a client's research facility, or our scientists can provide scalable contract research services.

Target Market(s): Pharmaceutical, biotech, research & development (proteomics), clinical and diagnostics.

Management

Randall W. Nelson PhD – Founder

20+ years at Senior Scientist Level

PhD. Chemistry – ASU

11+ years upper management Vestec Corp, IBI

Dobrin Nedelkov PhD – CEO & Director of Research and Development

10+ years at Senior Scientist Level

PhD. Biochemistry – ASU

Kemmons Tubbs PhD – Vice President Manufacturing

10+ years at Senior Scientist Level

PhD. Biochemistry – ASU

Monte L. Cain – Director of Business Development

20+ years business development, advertising and marketing.

Key Value Drivers

Technology*: MSIA™ - Tips (Mass Spectrometric Immunoassay) are affinity pipettes that selectively isolate proteins of interest out of complex biological fluids. BRP™ (Bioreactive Probes) are specialized 96 well MALDI plates that modify proteins in a way that is ideal for mass spec analysis. MASSAY® System incorporates the aforementioned technologies, robotic processes and proprietary bioinformatics tools to create a high-throughput solution capable of analyzing up to 2,500 samples per day of proteins obtained directly from biological media.

Competitive Advantage: IBI's technologies offer rapid, complete, qualitative and quantitative protein analysis. Our characterization techniques detect proteins based on exact molecular weights, thereby enabling analysis of dozens of proteins in a single assay with the ability to differentiate between wild-type and variant protein species. These characteristics offer the user significant advantages over previous technologies including cost, sample purity, and variety of analyzable proteins.

Plan & Strategy: seeking strategic partners to accelerate our commercialization goals.

Product Development

All products and technologies are fully developed, patented and have a full array of commercial applications. The strengths of IBI's products lie in their scalability for any research application, as well as their high throughput capability which exceeds other similar products. Presently IBI operates as a CRO utilizing its proprietary technologies.

